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Abstract: 
 
From the rice-based culture of Malbranchea flavorosea, three new compounds namely 
flavoroseoside B (5-desoxy-5-chloro-flavoroseoside) (2), 4-hydroxy-2-O-α-ribofuranosyl-5-
methylacetophenone (3), and (S)-3,4-dihydro-3-(1H-indol-3-ylmethyl)-4-methyl-1H-1,4-
benzodiazepine-2,5-dione (4), along with three known compounds, rosigenin (5), massarilactone 
B (6), and riboxylarinol B (7) were obtained. The structures were determined by spectroscopic 
methods. Compound 4 and its synthetic analog 3,4-dihydro-3-(1H-indol-3-ylmethyl)-1-methyl-
1H-1,4-benzodiazepine-2,5-dione (9) inhibited the activity of Ruminococus obeum α-glucosidase 
enzyme. Molecular docking and dynamic studies revealed that compounds 4 and 9 might bind to 
this α-glucosidase at the catalytic center. Phylogenetic analysis using internal transcribed spacer 
region revealed that Malbranchea flavorosea ATCC 34529 is related to Myxotrichum spp. 
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Article: 
 
Introduction 
 
The global prevalence of type II diabetes has risen considerably in the last 5 years; the 
International Diabetes Federation estimates that there are 425 million people with this disease, 
which is among the top 10 causes of death worldwide. Also, there is a significant economic 
impact due to the high cost of its treatment [1]. Hence, new therapies for diabetes are very 
relevant nowadays. Metformin is the first-line medication for the treatment of type II diabetes 
mellitus, while the use of other well-established agents varies in different regions. In areas with 
large consumption of complex carbohydrates, α-glucosidase inhibitors are widely used. These 
agents competitively and reversibly inhibit α-glucosidase enzymes located in the brush border of 
the small intestine, delaying the digestion of starch and sucrose and the consequent postprandial 
blood glucose excursions [2]. 
 
 
Figure 1. Structures of compounds 1–7 isolated from the fungus M. flavorosea, and related 
compounds 8 and 9 
 
As part of an effort to discover α-glucosidase inhibitor lead compounds from fungi and plants [3, 
4], we investigated Malbranchea flavorosea Sigler and Carmichael (Myxotrichaceae) in a 
previous work and identified flavoroseoside (1) (Fig. 1), 8-chloroxylarinol A, xylarinols A and 
B, massarigenins B and C, and clavatol [5]. Massarigenin C showed a good α-glucosidase 
inhibitory activity both in vivo and in vitro. Therein, we report the further chemical investigation 
of a rice-based culture of the fungus M. flavorosea, the α-glucosidase inhibitory activity of the 
isolates and taxonomic features of the fungus. 
 
Results and discussion 
 
Fungal strain and identification 
 
The fungal strain Malbranchea flavorosea Sigler & Carmichael (type strain: ATCC 34529) [6] 
was obtained from the American Type Culture Collection. Species in the genus Malbranchea are 
commonly isolated from soil, but also dung and cellulose; there are ~22 species reported in the 
literature [7]. Members of Malbranchea are phylogenetically affiliated to the Onygenaceae, 
Onygenales, Eurotiomycetes Ascomycota [8, 9], however, not all Malbranchea spp. have been 
identified based on molecular data and, for a number of species, the ITS barcodes are lacking. 
For M. flavorosea, one partial nuclear large subunit gene sequence is deposited in NCBI 
GenBank (AB359419), but since no published reference is associated with this accession 
number, the authenticity of the sequence cannot be verified. Therefore, we sequenced the type 
isolate of M. flavorosea (ATCC 34529) for the internal transcribed spacer region (ITS1-5.8S-
ITS2), which is designated as the barcoding marker for fungi [10] to predict its phylogenetic 
relationship with closest members in NCBI GenBank. DNA extraction, PCR, Sanger sequencing, 
and molecular phylogenetic analysis using maximum likelihood were performed following 
protocols that have been recently described [11]. The ITS sequences obtained (n = 4) were 
BLAST searched in GenBank to verify the identity and sequence homology with other similar 
ITS sequences in the public database. Based on a BLAST search of the NCBIs GenBank 
nucleotide database, the closest hit using the ITS sequence was Myxotrichum stipitatum 
[GenBank AF062816; Identities 479/493 (97%); Gaps 3/493 (0%)] [12], followed by 
Myxotrichum stipitatum strain SFCF20120912-11 [Gen-Bank KF313096; Identities 493/514 
(96%); Gaps 3/514 (0%)] [13], then by Myxotrichum carminoparum UAMH 159 [GenBank 
AF062812; Identities 459/494 (93%); Gaps 3/494 (0%] [12], and then followed by 
Myxotricheaceae [GenBank KC007174; Identities 779/895 (87%); Gaps (32/895) (3%)] [14]. To 
elucidate the phylogenetic placement of strain ATCC 34529, we downloaded the top matches of 
the ITS sequences from GenBank and carried out a phylogenetic analysis. Maximum Likelihood 
phylogeny indicated that strain ATCC 34529 showed phylogenetic affiliations to Myxotrichum 
spp. (Fig. 2). Members of Myxotrichum (Myxotrichaceae Locq. & Currah) were previously 
placed and considered related to the Onygenales, Eurotiomycetes; however, molecular 
phylogenetic studies place them in an uncertain, isolated position within the Leotiomycetes [12, 
15]. Thus, our data suggest that M. flavorosea shows phylogenetic relatedness to Myxotrichum 
spp. (incertae sedis Leotiomycetes, Ascomycota), which was reported by Sigler and Carmichael 
(1976) in their monograph on Malbranchea spp [6]. An older study on Malbranchea also 
indicated that M. flavorosea may have a Myxotrichum sexual state [16]. This analysis is 
preliminary and further sequencing of both ribosomal and protein-coding loci, along with 
additional phylogenetic analysis of Malbranchea, is necessary to better understand the 
phylogenetic disposition of this fungus. The sequence data are deposited in GenBank with 
accession numbers: MH037295, MH037296, MH037297, and MH037298. 
 
 
Figure 2. Phylogram of the most likely tree (−lnL = 1415.05) from a PHYML analysis of 11 
taxa based on the ITS region (533 bp). Numbers refer to PHYML bootstrap support values ≥ 
70% based on 1000 replicates. Malbranchea flavorosea (ATCC 34529) is phylogenetically 
related to Myxotrichum stipitatum (incertae sedis Leotiomycetes, Ascomycota). A 14-d-old 
culture on oatmeal media is shown. Bar indicates nucleotide substitutions per site 
 
Isolation of compounds 
 
Conventional fractioning of an active organic extract from the rice-based culture of M. 
flavorosea led to the isolation of three new compounds, flavoroseoside B (5-desoxy-5-chloro-
flavoroseoside) (2), 4-hydroxy-2-O-α-D-ribofuranosyl-5-methylacetophenone (3), and (3 S)-3,4-
dihydro-3-(1H-indol-3-ylmethyl)-4-methyl-1H-1,4-benzodiazepine-2,5-dione (4), along with 
rosigenin (5) [17], massarilactone B (6) [18], and riboxylarinol B (7) [19] (Fig. 1). 
 
Compound 2 was isolated as an optically active colorless glassy solid. Its molecular formula was 
established by HRESIMS as C15H17O8Cl, requiring 7 degrees of unsaturation. The presence of a 
chlorine atom in the molecule was consistent with the relative abundance of the [M+2] + peak 
with respect to the molecular ion [M+]. The IR spectrum showed a signal characteristic of 
chelated carbonyl (1664 cm−1) and phenol (1241 cm−1) groups. The NMR spectra (Table 1) 
showed strong similarities with those of flavoroseoside (1) [5]; comparative analyses revealed 
that the only difference was the chemical shift value of the signal attributed to C-5, which was 
diamagnetically shifted from δC 149.1 in 1 to δC 113.3 in 2, suggesting that the hydroxyl group in 
1 was replaced by a chlorine atom in 2. Since the CD spectra of 1 and 2 were identical, the 
absolute configuration of the methyl group at C-3 was determined to be R. In addition, the 
optical rotation sign was identical and the value was very similar of 2, suggesting that the 
ribofuranosyl unit also belongs to the D series. 
 
Table 1. 1H (700 MHz) and 13C (175 MHz) NMR data for compound 2 in CD3OD 
 
 
Table 2. 1H (700 MHz) and 13C (175 MHz) NMR data for compound 3 in CD3OD 
 
 
Compound 3 was isolated as a brown oil. HRESIMS yielded the molecular formula C14H18O7 
with 6 degrees of unsaturation. Based on NMR data (Table 2), 3 was determined to be a 
glycoside closely related to clavatol, which was previously isolated from this fungus [5]. The 
main difference between the NMR spectra of clavatol and 3 were the presence of signals for an 
α-ribofuranosyl moiety and the replacement of the 3-methyl group signal at δH/δC 2.11/7.43 by 
that of an aromatic methine proton (δH/δC 6.69/103.5). All carbon signals were assigned 
according to the HSQC and HMBC correlations. The HMBC cross peaks of H-6 (δH 7.64) with 
C-2 (δC 163.3), C-4, (δC 164.1), C-7 (δC 204.7), and C-9 (δC 15.8), as well as those of H-3 (δH 
6.69) with C-1 (δC 115.2) and C-5 (δC 120.5), corroborated the positions of the substituents along 
the aromatic core. The placement of the ribofuranosyloxy moiety at C-2 was confirmed by the 
HMBC correlation between H-1′ (δH 5.72) and C-2. Thus, compound 3 was characterized as 4-
hydroxy-2-O-α-ribofuranosyl-5-methylacetophenone. 
 
Table 3. 1H (700 MHz) and 13C (175 MHz) NMR data for compounds 4 (4a/4b) and 9 in CD3OD 
 
 
Compound 4 was isolated as a white amorphous solid. The molecular formula was determined as 
C19H17O2N3 by HRESIMS, which accounted for 12 unsaturation degrees. The IR spectrum 
showed bands due to amide and phenyl groups (1683 and 1619 cm−1). When the 13C NMR 
spectrum was recorded in CD3OD at room temperature, 38 signals were observed rather than 19 
as suggested by the molecular formula (Table 3). In the 1H NMR spectrum, all signals were 
observed also in pairs in a 1:1 ratio. However, when the 1H NMR was recorded in DMSO-d6 at 
50 °C, the two sets of signals merged into single resonances (Supplementary Information). 
Altogether, this information indicated that 4 existed as a mixture of two different stable 
conformers (4a/4b) at room temperature, and that the energy barrier for interconversion was 
significantly higher compared with the NMR time-scale. Comparative analysis of the NMR 
spectra of 4a/4b (Table 3) with those of 7-methoxycyclopeptin (8) [20] and related compounds 
[21] revealed strong similarities, albeit partial. Compound 8 is also a dipeptide of the 
benzodiazepinedione family, which at room temperature exists as a mixture of two conformers in 
a 5:4 ratio (8a/8b) [20]. The main differences observed in the NMR spectra of both compounds 
were the signals for the second amino acid and the presence of a methoxy group at the 
anthranilic derived residue. Thus, the signals for the phenylalanine residue in 8a/8b were 
replaced for those of a tryptophan residue in 4a/4b. On the other hand, the ABX system for the 3-
methoxyanthranilic residue of 8a/8b was replaced by an AAʹBBʹ system of an unsubstituted 
anthranilic acid moiety in 4a/4b. The negative value of the optical rotation ([𝛼𝛼]D20 = −57.7°) 
indicated that the absolute configuration of the only chiral center was S, suggesting that L-
tryptophan was the precursor of 4a/4b. During the characterization process, the 1-methylated 
analog 9 was synthesized as described in the experimental section, and its NMR data (Table 3) 
was similar to that of the conformer mixture 4a/4b; however, the signals were not paired, 
suggesting that the energy barrier for interconversion of 9 was lower compared with the NMR 
time-scale. 
 
Biological activity 
 
Compounds 2–6 and 9 were tested against recombinant α- glucosidase with maltase-
glucoamylase activity obtained from Ruminococcus obeum (Table 4; compounds 1 and 7 were 
not tested due to the paucity of sample) [22]. The benzodiazepinediones 4 and 9 displayed the 
best inhibitory activity against the enzyme (IC50 = 1.33 ± 0.05 and 1.68 ± 0.07 mM, 
respectively), while the activity of 2, 3, and 5 was weak (IC50 > 3 mM). Recombinant R. obeum 
α-glucosidase is a structural homologue of human N-maltase-glucoamylase; and possesses a 
highly conserved catalytic domain [22]. So, it is possible to make better inferences regarding the 
potential in vivo effects in humans of any compound assayed with this enzyme. Compounds 4 
and 9 were also tested against Saccharomyces cerevisiae α-glucosidase, showing a higher affinity 
for this enzyme (IC50 = 0.19 ± 0.02 and 0.54 ± 0.05 mM, respectively). Thus, 4 and 9 possess a 
better sucrase inhibitory activity. Although this is the first report of benzodiazepinediones as α-
glucosidase inhibitors, some dipeptides of the diketopiperazine family and a quinazolino-
benzodiazepine metabolite were reported as α-glucosidase inhibitors [23, 24]. 
 
Docking and molecular dynamics 
 
Molecular modeling studies indicate that the compounds with the highest affinity to the enzyme 
are 9, 2, and 4. Theoretical Ki values obtained from docking are shown in Table 4. According to 
the results of the docking analysis (Fig. 3), these compounds bind in the same site than acarbose 
(positive control); the amino acids involved in the interactions are: Asp197, Ile234, Tyr169, 
Trp271, Trp305, Asp307, Arg404, Trp417, Asp420, Phe453, and His478. Moreover, the 
energetic data (ΔG) obtained from the molecular dynamics (MD) trajectory analysis show that 
acarbose, 4 and 9 are the compounds that present the best binding (Table 4). These results agree 
with the experimental data obtained for this series of compounds. The root mean square 
deviation (RMSD) obtained from the analysis of MD trajectories indicate the degree of 
conformational flexibility of the system (α-glucosidase-ligand complexes). Figure 4 shows the 
comparison of the RMSDs of the complexes α-glucosidase-acarbose, α-glucosidase-4 and α-
glucosidase-9, which showed similar fluctuation. Figure 5 is a graphical representation of the 
trajectory of MD of the glucosidase-4 complex during 20 ns. This representation indicates how 
the compounds fluctuate in the catalytic site and are reoriented, just as the enzyme itself shows 
adjacent conformational changes. All the MD trajectories of the complexes are shown in movies 
in the Supplementary Information. 
 
Table 4. Inhibition parameters (in vitro and in silico) of compounds 1–9 against α-glucosidases 
 
NT not tested; a Positive control 
 
 
Figure 3. Structural model of complexes of α-glucosidase with acarbose (a) and 4 (b) from to 
docking study. α-Glucosidase represented in green cartoon and the amino acids involved in the 
catalytic site in green sticks. This figure was prepared using PyMOL 
 
Figure 4. The RMSD and time plot for a 20 ns MD simulation. α-glucosidase with acarbose 
(ACA) (—, black line), α-glucosidase without ligand (—, red line), α-glucosidase-4 complex (—
, blue line), and α-glucosidase-9 complex (—, pink line) 
 
 
Figure 5. Graphic representation of the MD simulation for the α-glucosidase-4 complex 
 
Materials and methods 
 
General experimental procedures 
 
IR spectra were recorded using a Perkin-Elmer 400 FT-IR or Perkin-Elmer 599B 
spectrophotometer. NMR spectra, including bidimensional, were recorded in CD3OD or DMSO-
d6 solution on a Bruker Avance III HD (Billerica, MA, USA) or a Varian VNRMS (Palo Alto, 
CA, USA) spectrometer at 700 MHz (1H) and 175 MHz (13C), using TMS as an internal 
standard. High-resolution mass spectra, HRMS (DART-TOF+), were acquired with a JEOL 
AccuTOF JMS-T100LC (Peabody, MA, USA) spectrometer. Optical rotations were obtained 
with a Perkin-Elmer 241 polarimeter. Preparative HPLC was carried out with a Waters 
instrument (Milford, MA, USA) equipped with a 2535 pump and a 2998 photodiode array 
detector, using a Gemini 5u C18 110Å (21.2 × 250 mm) or a Kinetex 5 μm C18 100Å (21.2 × 
250 mm) column, and different gradient systems of MeCN and 0.1% aqueous formic acid, at a 
flow rate of 21.24 ml/min. Control of equipment, data acquisition and processing, and 
management of chromatographic information were performed using the Empower 3 software. 
Column chromatography (CC) was carried out on Sephadex LH-20 (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK). Flash chromatography was done with a Teledyne CombiFlash 
Rf+Lumen (Thousand Oaks, CA, USA) chromatograph equipped with a photodiode array 
detector and an evaporative light-scattering detector, using a RediSep Rf high performance 
GOLD silica gel column and eluting with a gradient of hexane, chloroform and methanol. Thin-
layer chromatographic (TLC) analyses were performed on silica gel 60 F254 plates (Merck, 
Kenilworth, NJ, USA), and visualized using a Ce2(SO4)3 (10%) solution in H2SO4. 
 
Fungal material 
 
Malbranchea flavorosea was purchased from the American Type and Culture Collection (ATCC 
No. 34529). The lyophilized material was resuspended in 5 ml of sterile water and left overnight. 
Petri dishes containing potato-dextrose agar (Difco PDA, BD, Loveton Circle, Sparks, Maryland, 
USA) were inoculated using 200 μl of the previous suspension. Stock cultures of the fungus were 
stored in PDA and monthly subcultured for preservation. 
 
Fermentation, extraction, and isolation 
 
Seed cultures of the fungus were prepared using potato-dextrose broth (Difco PDB) media and 
incubation at room temperature for 15 days at 200 rpm. Next, M. flavorosea was grown on 
Erlenmeyer flasks containing 85 g of rice and 200 ml of water (5 × 500 ml). After 30 days of 
fungal growth, the culture media was exhaustively extracted with 8:2 CH2Cl2-MeOH (4 × 500 
ml), and the resulting extract was evaporated in vacuo to yield 21.7 g of a brown oily residue. 
The total extract was suspended in 150 ml of a mixture of MeCN-MeOH (1:1) and partitioned 
with n-hexane (8 × 150 ml). The combined MeCN-MeOH fractions were dried under vacuum, 
and the resulting residue (5.9 g) was dissolved in MeOH and subjected to flash chromatography 
using a gradient of n-hexane-CHCl3 (100:0→0:100, 10 min) and CHCl3-MeOH (100:0, 7.5 min; 
100:0→98:2, 7.5 min; 98:2→95:5, 7.5 min; 95:5→90:10, 12.5 min; 90:10→80:20, 20.0 min; 
80:20→0:100, 25.0 min). This separation yielded 10 primary fractions (FA–FJ). 
 
Fraction FF (540 mg), eluted with CHCl3-MeOH (90:10), was subjected to flash chromatography 
using a gradient of CHCl3-EtOAc (100:0→0:100, 7.0 min; 0:100, 9.0 min) and EtOAc-MeOH 
(100:0→99:1, 4.0 min; 99:1→97:3, 5.0 min; 97:3→94:6, 4.0 min; 94:6→90:10, 4.0 min; 90:10
→86:14, 5.0 min; 86:14→80:20, 4.0 min; 80:20→0:100, 3.0 min; 0:100, 15 min;). This 
separation yielded 7 tertiary fractions (FF1–FF7). Fraction FF3 was analyzed by CC eluting with 
CHCl3-MeOH (3:7) in four fractions (FF3a–FF3d). Fraction FF3c (76 mg) was subjected to 
preparative RP-HPLC using a gradient of MeCN-0.1% aqueous formic acid (10:90 for 5 min, 
then 10:90 to 15:85 in 15 min) to yield 5 (8 mg, tR 10.10 min). Fraction FF5 (87 mg) was 
subjected to preparative RP-HPLC using a gradient of MeCN-0.1% aqueous formic acid (20:80 
to 100:0 in 20 min) to yield 2 (1 mg, tR 8.56 min), 4 (3 mg, tR 10.53 min), 6 (5 mg, tR 6.16 min) 
and 7 (1 mg, tR 5.46 min). Fraction FG (160 mg), eluted with CHCl3-MeOH (85:15), was 
subjected to preparative RP-HPLC using a gradient of MeCN-0.1% aqueous formic acid (10:90 
to 100:0 in 25 min) to yield 3 (4 mg, tR 10.11 min). In fractions FC, FD, FE, FH, and FI, the 
previously isolated compounds from this fungus, 8-chloro xylarinol A, xylarinol B, clavatol, 
flavoroseoside, and massarigenins B and C were chromatographically detected. 
 
Flavoroseoside B (2): colorless glassy solid; [𝛼𝛼]D20 + 164.5° (c 0.1, MeOH); UV (λmax) 200.6, 
261.8, 312.9 nm; IR (νmax) 3363, 1664, 1614, 1241 cm−1; 1HNMR (700 MHz) and 13C NMR (175 
MHz) spectroscopic data in CD3OD, see Table 1; HRMS m/z 361.0684 [M+H]+ (calculated for 
C15H18O8Cl 361.0690). 
 
4-Hydroxy-2-O-α-ribofuranosyl-5-methylacetophenone (3): brown oil, [𝛼𝛼]D20 + 75.3° (c 0.1, 
MeOH); UV (λmax) 194.5, 222.4, 326.0 nm; IR (νmax) 3407, 1633, 1264, 1043 cm−1; 1H NMR 
(700MHz) and 13C NMR (175 MHz) spectroscopic data in CD3OD, see Table 2; HRMS m/z 
299.11305 [M+ H]+ (calculated for C14H19O7 299.1131). 
 
(S)-3,4-Dihydro-3-(1H-indol-3-ylmethyl)-4-methyl-1H-1,4-benzodiazepine-2,5-dione (4): white 
amorphous solid, [𝛼𝛼]D20 − 57.7° (c 0.1, MeOH); UV (λmax) 214.5, 281.9 nm; IR (νmax) 3229, 
1683, 1619, 739 cm−1; 1H NMR (700 MHz) and 13C NMR (175MHz) spectroscopic data in 
CD3OD, see Table 3; 1H NMR (700 MHz) spectroscopic data in DMSO-d6, see Supplementary 
Information (Figure S17); HRMS m/z 320.1398 [M + H]+ (calculated for C19H18O2N3 320.1399). 
 
Rosigenin (5): colorless glassy solid; 1H NMR (700 MHz, CD3OD) δ 6.88 (1 H, dd, J = 2.5, 10.2 
Hz, H-7), 6.01 (1 H, dd, J = 2.9, 10.2 Hz, H-8), 4.82 (1 H, quin, J = 6.5 Hz, H-3), 4.68 (1 H, d, J 
= 6.5 Hz, H-4), 4.44 (1 H, s, H-10), 3.21 (1 H, m, H-6), 1.36 (3 H, d, J = 6.7 Hz, H-11), 1.28 (3 
H, d, J = 7.2 Hz, H-12); 13C NMR (175MHz, CD3OD) δ 199.1 (C-9), 178.4 (C-1), 154.1 (C-7), 
125.4 (C-8), 81.8 (C-3), 76.9 (C-10), 75.6 (C-4), 61.9 (C-5), 34.9 (C-6), 18.8 (C-12), 14.6 (C-
11). 
 
Massarilactone B (6): white amorphous solid; 1H NMR (700 MHz, CD3OD) δ 5.88 (1 H, qdd, J 
= 0.8, 6.4, 12.8 Hz, H-12), 5.76 (1 H, m, J = 1.2, 8.4, 16.4 Hz, H-11), 4.92 (1 H, qd, J = 1.3, 6.8 
Hz, H-3), 4.82 (1 H, dd, J = 4.0, 8.2 Hz, H-6), 4.25 (1 H, dd, J = 1.4, 3.7 Hz, H-8), 3.77 (1 H, dd, 
J = 3.7, 4.1 Hz, H-7), 1.71 (3 H, dd, J = 0.9, 6.4 Hz, H-13), 1.41 (3 H, d, J = 6.8 Hz, H-10). 13C 
NMR (175MHz, CD3OD) δ 179.3 (C-4), 174.1 (C-1), 133.1 (C-12), 126.7 (C-11), 100.8 (C-9), 
86.3 (C-6), 75.5 (C-3), 72.6 (C-7), 64.1 (C-8), 17.9 (C-13), 17.8 (C-10). 
 
Riboxylarinol B (7): colorless glassy solid; 1H NMR (700 MHz, CD3OD) δ 7.11 (1 H, t, J = 7.7 
Hz, H-5), 6.74 (1 H, d, J = 7.4 Hz, H-6), 6.67 (1 H, d, J = 7.9 Hz, H-4), 5.38 (1 H, m, H-1ʹ), 5.09 
(1 H, dd, J = 2.6, 11.9 Hz, H-6ʹa), 4.98 (1 H, dd, J = 5.8, 11.9 Hz, H-6ʹb), 3.72 (1 H, m, H-4ʹ), 
3.66 (1 H, m, H-3ʹ), 2.09 (1 H, ddd, J = 3.6, 4.8, 14.3 Hz, H-2ʹa), 1.79 (1 H, dt, J = 8.3, 14.3 Hz, 
H-2ʹb), 1.20 (3 H, d, J = 6.4 Hz, H-5ʹ); 13C NMR (175 MHz, CD3OD) δ 152.8 (C-3), 145.2 (C-1), 
130.4 (C-5), 125.8 (C-2), 114.8 (C-6), 113.2 (C-4), 84.3 (C-1ʹ), 74.8 (C-4ʹ), 71.5 (C-3ʹ), 71.4 (C-
6ʹ), 40.1 (C-2ʹ), 18.5 (C-5ʹ). 
 
3,4-Dihydro-3-(1H-indol-3-ylmethyl)-1-methyl-1H-1,4-benzodiazepine-2,5-dione (9): white 
solid, mp. 217–219 °C; [𝛼𝛼]D20 − 89.9° (c 0.1, MeOH); UV (λmax) 214.5, 281.9 nm; IR (νmax) 
3340, 1650, 1463, 741 cm−1; 1H NMR (700 MHz) and 13C NMR (175MHz) spectroscopic data in 
CD3OD, see Table 3; HRMS m/z 320.1399 [M + H]+ (calculated for C19H18O2N3 320.1399). 
 
Synthesis of compound 9 
 
A mixture of N-methylisatoic anhydride (555 mg), D-tryptophan (575 mg), triethylamine (500 
μl) and H2O (8 ml) was stirred at room temperature for 5 h; then the volatile material was 
removed in vacuo. To the resulting residue, glacial acetic acid (12 ml) was added, the solution 
was then refluxed for 8 h. The reaction mixture was concentrated in vacuo and partitioned with 
EtOAc and H2O. The organic layer was washed with a solution of NaHCO3, followed by H2O 
(10 ml × 2) and then dried over anhydrous Na2SO4. Finally, the solvent was removed in vacuo to 
yield 450 mg of crude 9. The crude was recrystallized from MeOH (30 ml) to yield 360 mg of 
compound 9. 
 
Enzymatic assay 
 
Two types of enzymes were used in the enzymatic assay, α-glucosidase from R. obeum (α-Ro) 
and α-glucosidase from S. cerevisiae (α-GHY). For α-Ro assay, compounds 2–6, 9 and acarbose 
(positive control) were dissolved phosphate buffer solution (PBS, 25 mM, pH 7). For α-GHY 
assay, compounds 4, 9 and acarbose were dissolved in MeOH or phosphate buffer solution (PBS, 
100 mM, pH 7). Aliquots of 0-20 μl of testing materials (triplicated) were incubated for 10 min 
with enzyme solution (5 μl of 5.2 mg/ml α-Ro enzyme in PBS or 20 μl of 1 U/ml α-GHY 
enzyme in PBS). After incubation, 10 μl of p-nitrophenyl-α-D-glucopyranoside (20mM for α-Ro 
and 5 mM for α-GHY) were added and further incubated for 20 min for α-GHY or 3 h for α-Ro 
at 37 °C, and the absorbance measured at 415 nm. The inhibitory activity was determined as a 
percentage compared to the blank according to the following equation: 
%𝑅𝑅. 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 𝛼𝛼 − glucosidase = �1 −
𝐴𝐴415𝑏𝑏
𝐴𝐴415𝑐𝑐
� × 100% 
where % R. obeum α-glucosidase is the percentage of inhibition, A415c is the corrected 
absorbance of the samples under testing (A415 end − A415 initial), and A415b is the absorbance of the 
blank (A415 end blank − A415 initial blank). All assays were performed by triplicated. The IC50 was 
calculated by regression analysis, using the following equation: 
%Inhibition =
𝐴𝐴100
1 + � 1IC50
�
𝑆𝑆 
where A100 is the maximum inhibition, I is the inhibitor concentration, IC50 is the concentration 
required to inhibit activity of the enzyme by 50% ± SD, and s is the cooperative degree. 
 
Docking protocol 
 
Docking was done using the Protein Data Bank X-ray structure of α-glucosidase from R. obeum 
(3PHA.pdb); the structures of 1–9 were constructed using HyperChem 8 software (Hypercube 
Inc., Gainesville, FL) and later minimized using Gaussian 09, revision A.02 (Gaussian Inc., 
Wallingford, CT) at DFT B3LYP/3-21G level of theory. AutoDockTools 1.5.4 
(http://mgltools.scripps.edu/) was used to prepare the pdb files of α-glucosidase and the 
compounds. All hydrogen atoms and the Kollman united-atom partial charges were added to the 
protein structures, while Gasteiger-Marsili charges and rotatable groups were automatically 
assigned to the structures of the ligands. Blind docking was carried out with AutoDock 4.2 
(http://autodock.scripps.edu/) [25, 26] using the default parameters for the Lamarkian genetic 
algorithm. Electrostatic grid maps were generated for each atom type using the auxiliary program 
AutoGrid 4 that is part of AutoDock 4.2. The initial grid box size was 60 Å × 60 Å × 60 Å in the 
x, y, and z dimensions. Afterwards, a refined docking analysis was performed with a smaller grid 
box of 30 Å × 30 Å × 30 Å, centered at the previously identified ligand’s-binding site. Docking 
was evaluated with AutoDockTools 1.5.4 using cluster analysis, and the PyMOL software 
(Schrödinger, Cambridge, MA) [27]. 
 
Molecular dynamics simulation 
 
The complexes resulting from the docking study were processed with antechamber toolkit to 
generate suitable topologies for the LEaP module from AMBER 14 [28, 29]. Each structure and 
complex were subjected to the following protocol: hydrogens and other missing atoms were 
added using the LEaP module with the parm99 parameter set, Na+ counter ions were added to 
neutralize the system; the structures were then solvated in an octahedral box of explicit TIP3P 
model water molecules localizing the box limits at 12 Å from the protein surface. The total 
number of atoms in the simulated system was ~70,000, including solvent molecules. MD 
simulations were performed at 1 atm and 298 K, during 20 ns. They were maintained with the 
Berendsen barostat and thermostat, using periodic boundary conditions and particle mesh Ewald 
sums (grid spacing of 1 Å) for treating long-range electrostatic interactions with a 10 Å cutoff for 
computing direct interactions. The SHAKE algorithm was used to satisfy bond constraints, 
allowing to use a 2 fs time step for the integration of Newton’s equations as recommended in the 
AMBER package [28, 30]. Amber ff99SB and gaff force field [28, 31] parameters were used for 
all amino acid and organic molecules, respectively. The protocol consisted in performing an 
optimization of the initial structure, followed by a 50 ps heating step at 310 K, 50 ps for 
equilibration at constant volume and 500 ps for equilibration at constant pressure. Three 
independent 20 ns MD simulations were performed. Frames were saved at 100 ps intervals for 
subsequent analysis. The analyses were conducted with cpptraj [32] on the trajectory time 
intervals where the convergence criteria were met. We monitored the total energy of the system 
(including solvation) during the simulations and the pairwise mass-weighted RMSD on the alpha 
carbons backbone; C and N atoms were used as a metric. Binding free energies calculated by 
molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) [33, 34]. 
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